Andrew J. Armstrong, Md

This study is testing a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in men with a rare, aggressive form of prostate cancer that has spread. The goal is to see if this intensive treatment can stop the cancer from growing for at least 6 months an…